98 results about "Inosine" patented technology

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention relates to the technical field of molecular markers and animal genetic breeding, in particular to an SNP marker influencing the content of porcine inosine and application of the SNP marker. The 10 SNP molecular markers closely related to the porcine inosine content are researched and determined on the basis of American-series purebred landrace, American-series purebred large white pigs and American-series purebred duroc, the dominant allele frequency can be increased generation by generation by optimizing the dominant allele of the SNP, the inosine content can be reduced, and the molecular markers can be used for identifying the porcine inosine content. The pig genetic improvement progress is accelerated, so that the economic benefit of breeding pig breeding is effectively improved.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+ / Taurocholate Co-transporting Polypeptide (NTCP), and the target adenosine is the adenosine in the GAC codon coding for aspartic acid (D) at position 24 of the NTCP protein. The deamination of the adenosine changes the amino acid to a glycine (G). The RNA editing of the adenosine will result in a loss-of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.

The invention discloses a saccharomycetes lysate, a preparation method and application, and the main components of the saccharomycetes lysate comprise the following components accounting for the relative content of the saccharomycetes lysate: 93-98% of nucleoside, nucleotide and derivatives thereof; and 0.2 to 6% of amino acid; wherein the nucleoside, the nucleotide and the derivatives of the nucleoside and the nucleotide comprise one or more of adenosine, succinyladenosine, adenosine-3 '-phosphoric acid, inosine and S-adenosine homocysteine. Effect evaluation is carried out on the saccharomycetes lysate, and verification shows that the saccharomycetes lysate has the effects of whitening, repairing skin injury, preventing light and aging, resisting pollution and oxidation, resisting inflammation and relieving, protecting hair and preventing hair loss, replenishing water and preserving moisture, and enhancing skin vitality or removing dark circles.

The present invention addresses the problem of providing a medicine and a food composition for improving motor function. The present invention relates to a motor function improver comprising a combination of (a) one or more components selected from febuxostat and topiroxostat and (b) inosine.

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

Provided herein is a eukaryotic cell expressing an exogenously introduced inosine 5'-monophosphate dehydrogenase (IMPDH) that is resistant to a purine biosynthesis inhibitor, uses thereof for producing therapeutic agents and treating a disease or disorder, as well as pharmaceutical compositions and methods of making thereof.

Provided herein is an antisense oligonucleotide (ASO) for use in the prevention or treatment of a disease or a condition associated with ApoB in a subject, wherein the ASO effects site- directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous ApoB gene.

The present invention provides a therapeutic drug for frailty or muscular dystrophy, and particularly for sarcopenia, and a medicinal drug for improving motor function. The present invention provides a motor function improver that contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof and additionally contains an ATP precursor substance or is used in combination with an ATP precursor substance. The ATP precursor substance is preferably inosine, inosinic acid, or hypoxanthine. This motor function improver is preferably used as a medicinal drug and is used as a therapy or preventive for frailty and sarcopenia and as a therapy or preventive for muscle wasting and muscle loss.

An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.

This disclosure provides methods for treating neurodegenerative diseases and restoring neuronal synaptic function by administering adenosine-to-inosine editing modifiers.

The invention discloses a preparation method of 1, 7-dimethylxanthine, which adopts inosine as a starting material, and the developed catalyst porphyrin-loaded xanthine oxidase and nano metal oxide can be recycled for multiple times, thereby greatly lowering the production cost. More importantly, safety accidents occur frequently in recent years, a route design strategy for avoiding dangerous reactions becomes more and more important, and the route avoids the use of a diazotization dangerous process, so that the production safety risk is greatly reduced.

The invention relates to a biomarker for evaluating progression and prognosis of paraquat poisoning and application of the biomarker. The biomarker is a urine metabolite Inosine. Urine non-target metabonomics analysis shows that the level of the Inosine is low in urine of a patient suffering from early paraquat poisoning, is gradually reduced along with aggravation of the illness state and is remarkably increased in follow-up visit of five years; the prediction efficiency is judged according to the area (AUC) below the working characteristic (ROC) curve of a subject, the Anosine has good efficiency (AUC = 0.806) in judging the progression of paraquat poisoning, has good efficiency (AUC = 0.816) in judging the prognosis aspect in 1-4 days at the early stage of poisoning, and has excellent efficiency (AUC = 0.961) in judging the prognosis aspect in 7-14 days at the progression stage of poisoning. Moreover, the efficiency of the Inosine in predicting the progress and prognosis of paraquat poisoning is better than that of blood routine indexes (such as the number of leukocytes, the percentage of neutrophils and the percentage of lymphocytes) reported in the literature. In conclusion, as the biomarker for prognosis and prognosis of paraquat poisoning, the Inosine shows a good clinical application prospect.

The present invention relates to methods and compositions for disrupting interaction of an NRF2 protein and a KEAP1 protein. The methods include contacting at least one polynucleotide selected from the group consisting of a polynucleotide encoding the NRF2 protein and a polynucleotide encoding the KEAP1 protein with a guide oligonucleotide that effects one or more (e.g., at least two) adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alterations in said at least one polynucleotide, wherein the adenosine to inosine alterations generate a mutant amino acid, thereby disrupting interaction of the NRF2 protein and the KEAP1 protein. The invention also relates to methods of treating a KEAP1-NRF2 pathway related disease in a subject in need thereof, the method comprising contacting, within the subject, at least one polynucleotide selected from the group consisting of a polynucleotide encoding an NRF2 protein and a polynucleotide encoding a KEAP1 protein with a guide oligonucleotide that effects an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration in said at least one polynucleotide, wherein the adenosine to inosine alteration generates a mutant amino acid, thereby disrupting interaction of the NRF2 protein and the KEAP1 protein and treating the disease in the subject; and compositions thereof.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

Provided are methods of manufacturing cells. The methods comprise expanding cells in the presence of inosine, and harvesting the cells after expansion. In certain embodiments, the cells are genetically modified. For example, the cells may be genetically modified to express an engineered receptor, non-limiting examples of which are chimeric antigen receptors (CARs), engineered T cell receptors (TCRs), and the like. According to some embodiments, the cells are immune cells, e.g., T cells or natural killer cells. Also provided are populations of cells manufactured according to the methods of the present disclosure. Also provided are methods comprising administering an effective amount of a population of cells manufactured according to the methods of the present disclosure to a subject in need thereof. In certain embodiments, the subject has cancer, and the cells express an engineered receptor that binds to a tumor antigen on the surface of cells of the cancer.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium adolescentis BN18 and its postbiotics for lowering uric acid and improving gout symptoms, and their applications. The Bifidobacterium adolescentis BN18 can promote the degradation of inosine and guanosine, thereby reducing uric acid levels in the blood. The postbiotics for Bifidobacterium adolescentis BN18 are made from carefully selected raw materials such as carrots, winter melon, blueberries, apples, lemons, and fructooligosaccharides as the core components of the composition. Through deep fermentation with BN18, the resulting postbiotics not only reduce the activity of xanthine oxidase and lower uric acid levels in the blood, thus promoting uric acid reduction, but also significantly enhance their antioxidant properties, reducing inflammatory responses, lowering inflammation levels, alleviating joint pain, and improving gout symptoms.

The present application relates to the field of bioengineering, and particularly relates to a protein mutant capable of improving the nucleoside yield of a strain and application thereof. The present application performs point mutation on adenine deaminase and pyrimidine nucleotide transport protein, which can effectively accumulate the inosine, adenosine and other nucleoside related products produced by the strain, does not affect the growth of the bacterial body, has wider practicality, and is conducive to reducing the cost of industrial production of nucleosides.

Provided is an immunogenic composition for use in raising immunity against the agent of Lyme disease. The composition is based on variants of CspZ and comprises a polypeptide of SEQ ID NO: 1, except that (a) the amino acid whose position corresponds to amino acid 188 of SEQ ID NO: 1 is any amino acid other than tyrosine; and the amino acid whose position corresponds to amino acid 192 of SEQ ID NO: 1 is any amino acid other than tyrosine; and (b) one or both of the amino acids acid whose position corresponds to amino acid 164 of SEQ ID NO: 1 may be an amino acid other than inosine and an amino acid whose position corresponds to amino acid 168 of SEQ ID NO: 1 may be an amino acid other than cysteine. Also provided is a polynucleotide encoding any of the foregoing polypeptides and a method of vaccinating against Lyme disease comprising administering the polypeptide or RNA encoding the polypeptide to a subject.

This disclosure relates to improved methods of identifying A-to-I RNA edits in a sample. In certain embodiments, this disclosure relates to methods of purifying RNA containing an inosine base comprising the steps of: exposing an RNA sample to endonuclease V or fusion thereof and calcium ions in the absence of magnesium ions providing an RNA and endonuclease V binding complex. In certain embodiments, the methods further comprise purifying the RNA and endonuclease V binding complex from unbound RNA in the sample; separating the RNA from endonuclease V providing separated RNA; sequencing the separated RNA; and identifying positions in the RNA sequences wherein A-to-I edits occur. In certain embodiments, the RNA is derived from a cell.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus mucus fermentation SAU-C-1M and application thereof. The invention provides lactobacillus mucus SAU-C-1M, which is preserved in the China General Microbiological Culture Collection Center on July 10, 2025, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.35184. The lactobacillus mucus SAU-C-1M has the advantages that the lactobacillus mucus SAU-C-1M is preserved in the China General Microbiological Culture Collection Center on July 10, 2025; the lactobacillus mucilaginosus SAU-C-1M disclosed by the invention has the capability of degrading inosine and guanosine, has certain inhibition capability on xanthine oxidase, and has extremely high development value and practical value.

This invention discloses the application of inosine in the preparation of drugs that promote testosterone secretion, belonging to the field of biomedical technology. The effective active ingredient of the above-mentioned drugs is only inosine or its pharmaceutically acceptable salts. The dosage forms of the above-mentioned drugs are tablets, capsules, oral liquids, lozenges, granules, powders, pills, powders, ointments, elixirs, suspensions, powders, or injections. The routes of administration of the above-mentioned drugs are oral, transdermal, intramuscular, subcutaneous, or intravenous injection. Since inosine exists under physiological conditions and can be metabolized by intestinal microorganisms, reasonable supplementation of inosine is a safer and more effective method for restoring testosterone. Inosine helps maintain the homeostasis of the intestinal flora, and the experimental results of this invention further show that inosine can restore the damaged intestinal barrier, thus making it safer. Moreover, this invention does not directly supplement exogenous testosterone, therefore it is less likely to induce spermatogenesis disorders or promote prostatic hyperplasia.

The invention relates to the technical field of biologic detection of metabolomics, in particular to an OSAHS metabolism marker, a diagnosis model and application of the OSAHS metabolism marker and the diagnosis model. The metabolic marker comprises a red blood cell metabolite and / or a plasma metabolite; erythrocyte metabolites comprise L-aspartic acid, D-ribose-5-diphosphoric acid, cadaverine, 12, 13-epoxy octadecenoic acid, L-arginine, N-acetylmethionine, 5-hydroxyeicosatetraenoic acid, 13-oxo-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 10-tetrahydroxy-9Z, the component A is one or more of 11E-octadecadienoic acid, inosine monophosphate, nicotinamide, alpha-lactose, sphingosine, hydroxy octadecadienoyl or glyceraldehyde-3-phosphoric acid; the plasma metabolite is prepared from one or more of fumaric acid, cadaverine, L-aspartic acid, malic acid, sphingosine-1-phosphoric acid, L-arginine, cysteine-S-sulfate, thiosulfate, gamma-glutamyl alanine, galacturonic acid or vitamin B2.

The present disclosure provides, for instance, a method of detecting and quantifying RNA modifications. The RNA modification may be, for example, m6A, m6Am, m1A, hm5C, m5C, Ψ, or inosine. The method can comprise contacting the RNA with an antibody that binds the modification, and using a bar code approach to quantify the amount of RNA.

This invention provides mutants of L-threonine 3-dehydrogenase and uracil permease, and their applications. This invention achieves mutation of L-threonine 3-dehydrogenase by modifying the tdh gene to mutate the 282nd amino acid from V to another amino acid (such as E, A, or G); and / or, by modifying the pyrP gene to mutate the 283rd amino acid of uracil permease from V to another amino acid (such as M, A, or L), thereby increasing the nucleoside production capacity of microorganisms. The L-threonine 3-dehydrogenase mutant strains and / or uracil permease mutant strains provided by this invention have a significant promoting effect on the production of the target products adenosine and inosine. These L-threonine 3-dehydrogenase mutants and / or uracil permease mutants and their recombinant microorganisms provide a reference for the construction of production strains that produce adenosine, inosine, and derivatives using these as precursors.

A reverse transcription (RT) assay to directly detect chemical adducts on RNA. A fluorescence quenching assay to detect RT polymerization was optimized and employed to detect N 1-alkylation of inosine, an important post-transcriptional modification, using a phenylacrylamide as a model compound. The methods and composition may be expanded to identify novel reagents that form adducts with RNA, regardless of the primary sequence, and further explored to understand the relationship between RT processivity and natural post-transcriptional modifications in RNA.

The invention relates to the field of microorganisms, in particular to a plant lactobacillus and application thereof. The invention provides lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is GDMCC 66229. The lactobacillus plantarum has the advantages that the preservation number is CGMCC 66229, and the preservation number is CGMCC 66229; the lactobacillus plantarum SCUT732 provided by the invention has excellent acid resistance and bile salt resistance, has good beta-glucosidase activity, and has excellent capability of degrading uric acid precursor inosine and guanosine.

This invention provides a kit for the simultaneous detection of nine flavor nucleotides in livestock and poultry products. The flavor nucleotides are cytidine monophosphate, uridine monophosphate, guanylic acid, inosine monophosphate, adenosine monophosphate, hypoxanthine, inosine, adenosine diphosphate, and adenosine triphosphate. The kit includes: a high-concentration extraction reagent, a standard curve solution, a high-concentration phosphate buffer solution, pH adjustment solution A, and pH adjustment solution B. The high-concentration extraction reagent is perchloric acid; the standard curve solution is a mixed solution of the nine flavor nucleotides; the high-concentration phosphate buffer solution is a solution of potassium dihydrogen phosphate and dipotassium hydrogen phosphate; pH adjustment solution A is sodium hydroxide; and pH adjustment solution B is phosphate. This invention also provides a method for the simultaneous detection of the nine flavor nucleotides using the above kit. This invention enables the simultaneous determination of the content of nine flavor nucleotides in livestock and poultry products. The method is simple, rapid, accurate, and sensitive, and can be used for batch determination, showing good prospects for practical application.